Back to search results

A Study of MK-3120 for Advanced Solid Tumors

This study is investigating a new treatment called MK-3120 for people with advanced solid tumors. Advanced means the cancer has spread and cannot be removed by surgery. Solid tumors are cancers in organs and tissues, not in blood. The main goal is to understand how safe MK-3120 is and how well people tolerate it. You may be able to join if you are 18 or older, have an advanced solid tumor, and have already tried or cannot tolerate other available treatments. The study will measure side effects and how many people stop treatment due to side effects over approximately 42-43 months. The current recruitment status is unclear, and the study plans to enroll about 270 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 270 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to approximately 43 months to monitor for adverse events and up to approximately 42 months for discontinuing treatment due to adverse events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06818643

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Recruiting
PHASE1Ages 18+InterventionalTreatment
Merck Sharp & Dohme LLC
~270 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:MK-3120

At a glance

Recruiting sites
49 of 49 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants Who Experience an Adverse Event (AE)
Measured over Up to approximately 43 months
+1 more outcome measured

Conditions

Advanced Solid Tumors
Malignant Neoplasm

Explore related trials

Solid NeoplasmHepatitis C Infection

Where it's being run

49 sites across 35 states
Region M. de Santiago4
South Korea4
Texas3
Israel3
Turkey (Türkiye)3
North Holland2
Taiwan2
Alabama1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

Toll Free Number
[email protected]
1-888-577-8839
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
If hepatitis C virus (HCV) infected, must have undetectable HCV viral load

Exclusion

Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
Has uncontrolled significant cardiovascular disease or cerebrovascular disease
Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Known additional malignancy that is progressing or has required active treatment within the past 2 years
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Active infection requiring systemic therapy, with exceptions
History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
Has HBV or HCV infection

What this trial measures

  • Number of Participants Who Experience an Adverse Event (AE)Up to approximately 43 months

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.

  • Number of Participants Who Discontinue Study Treatment Due to an AEUp to approximately 42 months

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.